Publications
Mobile foot measurement’s IP battle highlights easily overlooked step in startup journey, Managing IP, 2026
In an article for Managing IP, Dr Christian Meyer of Maiwald, in collaboration with Footprint Technologies, explains how a single process patent has had a significant impact o...
Continue reading
Preliminary Injunctions in German Pharmaceutical Patent Litigation, Newsletter of the AIPLA Chemical Practice Committee, Spring 2026, Volume 14, Issue 1
In his article “Preliminary Injunctions in German Pharmaceutical Patent Litigation”, published in the Newsletter of the AIPLA Chemical Practice Committee, Spring 2026, Vol...
Continue reading
Worldwatch “Patent Litigation” – Apr–Jun 2026 (Corporate Disputes Magazine)
The Apr–Jun 2026 issue of Corporate Disputes Magazine features the Worldwatch section on “Patent Litigation,” with Maiwald partner and UPC representative
Continue reading
Clinical Trial Inventions in the Squeeze: The New Transparency Rules for Clinical Trials in the EU and the Assessment of Patentability by the EPO and the UPC, epi information, 1/2026
The article examines how the EU’s new transparency framework for clinical trials affects patentability assessments for inventions arising in the clinical phase. From both a ...
Continue reading
Patent handbooks published by Maiwald attorneys
Handbook Pharmaceutical, Biological and Chemical Patents To order these books at a special discount...
Continue reading
Podcast: „From idea to IP: navigating AI patents in a fast-moving field“
New podcast: “From idea to IP: navigating AI patents in a fast-moving field” How can AI inventions be successfully pat...
Continue reading
G 2/24 in a nutshell: EBoA clarifies intervener status in EPC appeals
In G 2/24, the EPO’s Enlarged Board of Appeal confirmed that an intervener in EPC appeal proceedings remains a dependent party and cannot continue the case after all appeals...
Continue reading
EU provisionally approves framework for new genomic technique plants from 2028
EU member states and the European Parliament have provisionally agreed a new regulatory framework for plants produced by new genomic techniques (NGTs). The deal creates two pa...
Continue reading
KI-Compliance: Zur Wechselwirkung von Sorgfaltsmaßstab und Vertrauensschutz beim Einsatz von ChatGPT – Vertrauen schützen, Sorgfalt wahren, Betriebs-Berater, 45/2025, (Article in german)
With the AI Act, the EU legislator has set out to establish a legal framework for trustworthy AI. However, a harmonized EU-level regime on AI liability is, for the time being,...
Continue reading
Filing of a protective letter before German Courts and before the Unified Patent Court
Continue reading
‘Missed opportunity’ as SPCs caught between human and veterinary medicinal products, Managing IP, 2025
The conditions for the grant of a supplementary protection certificate (SPC) have, since the SPC Regulation entered into force in 1993, been the subject of numerous national d...
Continue reading
Patentable AI applications under the EPC – from the technical perspective (English only)
Fabian Kiendl and Christian Schäflein examine how AI engineering can yield patentable inventions and consider the protection of such solutions in automotive technology under ...
Continue reading
How UPC’s first ruling on second medical use infringement reflects German practice, ManagingIP 2025
In its ruling on EP 3 536 712 B1, the Düsseldorf Local Division of the UPC for the first time outlined crucial criteria for patent infringement based on second medical use cl...
Continue reading
EU regulation on plants from new genomic techniques: green shoots of progress? ManagingIP 2025
In a specialist article, Kerstin Wolff analyzes the current state of EU regulation on new genomic techniques (NGTs). In February 2024, the European Parliament proposed exempti...
Continue reading
Managing IP Awards interview: Maiwald
ManagingIP June 10, 2025
In their recent feature with Managing IP, senior representatives from Maiwald – Dr. Anja Fux, Dr. Derk Vos, Heike Roeder-Hitschke, Dr. Nils Braun and Martina Boidol...
Continue reading
Safe Harbor Provision in European Patent LawThe Research & Bolar Exemptions, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025
This article covers the most recent developments regarding the European Research Exemption, which permits the use of patented inventions for research purposes, as well as the ...
Continue reading
The ‘long-arm’ of the Unified Patent Court – New developments in European cross-border patent litigation, AIPLA Chemical Practice Chronicles Newsletter, Volume 13 Issue 1 2025
The jurisdictional reach of the Unified Patent Court (UPC) was a widely and controversially discussed topic from the outset. Some practitioners took the view that the UPC also...
Continue reading
Statistics and Takeaways from Continued Application of G 2/21 by the EPO’s Boards of Appeal and First Impressions from the UPC on “Plausibility” epi Information, 1/2025
In G 2/21 of March 23, 2023, the Enlarged Board of Appeal (EBA) decided on the requirements for reliance on a purported technical effect for supporting inventive step, which i...
Continue reading
Germany permits service of claims on Chinese defendants by publication, Managing IP 2025
German courts now allow the service of claims on Chinese defendants by publication to ensure effective legal protection. The Regional Court of Frankfurt am Ma...
Continue reading
Äquivalente Patentverletzung in unterschiedlichen Jurisdiktionen, kandidatentreff Blog 2025
The article examines the different approaches to equivalent patent infringement in Europe and shows how case law has developed depending on the country. The focus is on the Pe...
Continue reading
Maity et al. (2020), Cancer Cell Specific Drug Delivery by a Tumor-Homing CPP-Gossypol Conjugate Employing a Tracelessly Cleavable Linker. Chem. Eur. J.
Continue reading
Germany: new filing options for UPC users and strategic considerations for patent challengers in Europe, IAM 2025
This article discusses some aspects that arose as a direct or indirect consequence of the entry into force of the Unified Patent Court (UPC) Agreement on 1 June 2023 at German...
Continue reading
After two years of G 2/21 case law, is the interpretation now settling? Managing IP, 2025
In their recent publication in Managing IP, Dr. Eva Ehlich and Dr. Anja Fux discuss a board of appeal decision on G 2/21’s interpretation, including a critical review of the...
Continue reading
EU seeks harmonisation of privilege for generic market entry, Managing IP 2025
Dr. Christian Meyer and D. Gisela Grabow explore proposed changes to new EU provisions aimed at facilitating faster market entry for generics and biosimilars, so as to alleged...
Continue reading
Proposed regulations for a unitary SPC for medicinal products under the microscope, Managing IP 2024
Dr. Christian Meyer and Dr. Gisela Grabow of Maiwald consider proposals under the European Commission’s Action Plan for Intellectual Property that aim to simplify extended p...
Continue reading
Interview IAM Strategy 300 Global Leaders, 2024
This year, IAM has once again invited leading experts in the field of intellectual property to provide valuable insights, highlight key experiences and share their views on th...
Continue reading
EU pharmaceutical reforms propose changes to regulatory protection periods, Managing IP 2024
Dr. Christian Meyer and Dr. Gisela Grabow discuss potential changes to the EU pharmaceutical regulation and their possible impact on data and market protection timelines for m...
Continue reading
Year Two – The Unitary Patent and the Unified Patent Court at a Glance, AIPLA Chemical Practice Chronicles Newsletter, Vol. 12 Issue 2, 2024
We can now look back on a quite successful first year of the new European patent and court system. Now well into its second year, the Unitary Patent (UP) continues to grow in ...
Continue reading
Patenting medical treatments in the US and Europe – a guide for practitioners, Managing IP 2024
Dr. Eva Ehlich & Dr. Anja Fux from Maiwald and Eldora Ellison, Paul Calvo & Sara Keeble from Sterne Kessler analyze how patents with claims directed to medical treatme...
Continue reading
Patent revocation actions under the new European patent system: UPC vs. EPO and why it may be wise to reappraise your European filing strategy, The Patent Lawyer Magazine September/October, 2024 (Page 22)
Continue reading
Die Marktexklusivität als absolutes Recht (Teil II), GRUR 16/2024
Although market exclusivity for orphan drugs (drugs for rare diseases) and the related non-indication-related document and marketing protection are crucial for ensuring invest...
Continue reading
Wündisch/Zirkel, F&E-Verträge, Handbuch für Wissenschaft und Praxis, 2024 (German only)
Chapter on the Unified Patent Court and Unitary Patent and on the special features of research and development in the pharmaceutical and life sciences sector
Our colleague Dr. Marco Stief has been given t...
Continue reading
Judgment of the Italian Supreme Court on the so-called Bolar Exemption, 2024 (avialable in English)
Continue reading
Podcast – Empowering women and nurturing young talent: Maiwald’s commitment to equality and diversity, MIP, 2024
Five female patent attorneys at Maiwald, spanning several age groups and practice areas, explain how the intellectual property firm encourages the career development of women ...
Continue reading
Is the medical use disclosure standard different for novelty and sufficiency?, Managing IP, 2024
Eva Ehlich and Anja Fux of Maiwald discuss an EPO board ruling ...
Continue reading
Promoting women and young talent at MAIWALD, 2024
Maiwald, a leading German IP law firm, has 45% female partners, emphasizing equality and diversity. The firm supports women's career advancement and attracts talented women th...
Continue reading
Offshore wind power and territoriality principles from a German viewpoint, Managing IP 2024
Claus Schindele considers the legal complications regarding patent protection in the offshore wind sector, with a particular eye on Germany and the UK
Continue reading
Die Marktexklusivität als absolutes Recht (Teil I), GRUR 11/2024
Investment and innovation protection are closely linked in the pharmaceutical sector for the development and marketing of new medicinal products. In addition to patent protect...
Continue reading
Unlocking Intellectual Property Efficiency: A comparative analysis of the EP patent, the DE patent, the German Utility Model, and the Unitary Patent, Women´s IP World annual, 2024
Continue reading
European Parliament addresses thorny issue of plants generated by new genomic techniques, Managing IP 4/2024
In her article published by Managing IP,
Continue reading
Wettbewerbsrecht im Kontext von Technologietransfer- und Lizenzverträgen, PharmR 4/2024
EU competition law in the context of technology transfer, license and settlement agreements: Since at least the initiation of the first pharma sector inquiry in 2008, the phar...
Continue reading
Reliance on a purported technical effect for inventive step – Quo vadis “plausibility” after G 2/21? epi Information, 1/2024
In the context of the effect-driven assessment of inventive step under the European Patent Convention (EPC) it is usually crucial for the outcome whether an Applicant/a Patent...
Continue reading
Not without my consent – Zu den Grenzen des SPC squatting, GRUR 6/2024
SPC for pharmaceutical products are an important complement to patent protection which is often inadequate in commercial terms. SPCs are designed to ensure that originators ca...
Continue reading
Wettbewerbsrecht im Kontext von F&E- und Linzenzverträgen, PharmR 3/2024
In the trade journal Pharma Recht (46th year, 15 March 2024), Dr. Marco Stief deals with the competition law assessment of research, cooperation and development agreements, wi...
Continue reading
§ 945 ZPO – Ausweitung der Haftung der Originatoren bei später widerrufenem Patent?, GRUR 4/2024 (Stief/Meyer)
In a recent article published in GRUR 2024, 182 et seqq.,
Continue reading
Products eligible for the medical use format under the EPC: new insights, Managing IP 2024
In the latest article published by Managing IP, Dr. Eva Ehlich and ...
Continue reading
T 0116/18 and a review after 10 months of G 2/21, Managing IP 2024
Decision on inventive step casts new light on EBA’s ‘plausibility’ guidance - Dr. Eva Ehlich and
Continue reading